Zobrazeno 1 - 5
of 5
pro vyhledávání: '"J Barral Juez"'
Autor:
MT Artola Urain, G Liceaga Cundin, M Umerez Igartua, O Valbuena Pascual, JJ Ferreiro Martinez, P Carmona Oyaga, I Fernandez Gonzalez, MP Bachiller Cacho, J Barral Juez, A Asensio Bermejo
Publikováno v:
European Journal of Hospital Pharmacy. 21:A136.2-A137
Background When an unrelated donor is used for an allogeneic hematopoietic stem cell transplant (AlloHSCT) highly immunosuppressive treatment is needed during the early post-transplant period as prophylaxis against acute graft versus host disease (aG
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ec8aafd1c5ba9be045ce863fdc00e49
https://doi.org/10.1136/ejhpharm-2013-000436.336
https://doi.org/10.1136/ejhpharm-2013-000436.336
Autor:
A Lizardi Mutuaberria, M Umerez Igartua, M Barral Juez, MP Carmona Oyaga, J Barral Juez, A Asensio Bermejo, P Pascual Gonzalez, G Lopez Arzoz, G Lizeaga Cundin, MP Bachiller Cacho
Publikováno v:
European Journal of Hospital Pharmacy. 21:A35.1-A35
Background Oral chemotherapy against metastatic or advanced renal-cell carcinoma (mRCC) is currently benefiting from a wide range of possibilities. Purpose To analyse the effectiveness of the actual therapy for the treatment of the mRCC in real condi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::316cfa0da01882468fdc58566dd3626f
https://doi.org/10.1136/ejhpharm-2013-000436.84
https://doi.org/10.1136/ejhpharm-2013-000436.84
Autor:
MJ Gayan Lera, C Ripa Ciaurriz, P Carmona Oyaga, N Mauelon Echeverria, J Barral Juez, B Odriozola Cincunegui, M Umerez Igartua, P Pascual Gonzalez, K Andueza Granados, M Ercilla Liceaga
Publikováno v:
European Journal of Hospital Pharmacy. 20:A164.2-A164
Background One of the clinical pharmacist’s main functions in parenteral nutrition is to ensure the quality and safety of the solutions prepared. It is too laborious to do this with each preparation. So in our hospital it was decided to design 21 s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::146e0de6b66e18ff37c612336146e937
https://doi.org/10.1136/ejhpharm-2013-000276.455
https://doi.org/10.1136/ejhpharm-2013-000276.455
Autor:
I Fernandez Gonzalez, MP Bachiller Cacho, M Iglesias Gaspar, P Pascual Gonzalez, M Umerez Igartua, O Valbuena Pascual, P Carmona Oyaga, G Lizeaga Cundin, J Barral Juez, A Asensio Bermejo
Publikováno v:
European Journal of Hospital Pharmacy. 20:A201.1-A201
Background Multiple myeloma (MM) is a malignant monoclonal gammapathy that occurs mainly in patients over 65 years. Lenalidomide is indicated in combination with dexamethasone for the treatment of MM in patients who have received at least one prior t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9653244b30b06cb7787d218b8379484
https://doi.org/10.1136/ejhpharm-2013-000276.557
https://doi.org/10.1136/ejhpharm-2013-000276.557
Autor:
P. Martín Andrés, MJ Gayan Lera, L Gómez de Segura Iriarte, P Carmona Oyaga, L Leunda Eizmendi, E. Esnaola Barrena, J Barral Juez, A Asensio Bermejo, P Pascual Gonzalez, I. Aranguren Ruiz
Publikováno v:
European Journal of Hospital Pharmacy. 19:112.3-113
Background It is necessary to monitor the effect of erythropoietin (EPO) on haemoglobin (Hb) levels to check the efficacy and safety of the medicine. The desirable therapeutic range of Hb according to the product information is from 10 to 12 g/dl and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd2ce1716d2c8aa8dd1fcc1249af3323
https://doi.org/10.1136/ejhpharm-2012-000074.73
https://doi.org/10.1136/ejhpharm-2012-000074.73